Patients with type 2 diabetes (T2D) and nephropathy, also known as diabetic nephropathy (DN), are at significant risk of developing end-stage renal disease (ESRD), a condition associated with extreme morbidity/mortality and high cost of care. Current therapies are unable to prevent progressive renal decline once initial DN sets in. As a result, physicians report substantial unmet need for safe and efficacious therapies for this indication. This unmet need represents significant commercial opportunity, one that drug developers have been quick to realize. Understanding the importance of key efficacy, safety and tolerability, and nonclinical attributes to the prescribing decisions for DN will be paramount to developing a successful therapy.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 U.S. and 30 European endocrinologists and nephrologists, fielded in January 2017.
Key companies: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, AbbVie, Bayer HealthCare, Janssen
Key drugs: Jardiance, Victoza, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), atrasentan, finerenone, canagliflozin